Please provide your email address to receive an email when new articles are posted on . A clinical-stage biopharmaceutical company has reported new positive data from a 12-month long-term open label ...
– Virtual investor webcast today at 8:00 a.m. EDT – “We are pleased to complete the positive registrational trial for our brilaroxazine program in schizophrenia and generate long-term data reinforcing ...
LA JOLLA, Calif.--(BUSINESS WIRE)-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback